Cargando…
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cispla...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031877/ https://www.ncbi.nlm.nih.gov/pubmed/35458666 http://dx.doi.org/10.3390/molecules27082466 |
_version_ | 1784692501086470144 |
---|---|
author | Tsvetkova, Dobrina Ivanova, Stefka |
author_facet | Tsvetkova, Dobrina Ivanova, Stefka |
author_sort | Tsvetkova, Dobrina |
collection | PubMed |
description | The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin, Heptaplatin, and Satraplatin. The literature data show that the strategies for the development of platinum anticancer agents and bypassing of resistance to Cisplatin derivatives and their toxicity are: combination therapy, Pt IV prodrugs, the targeted nanocarriers. The very important strategy for the improvement of the antitumor effect against different cancers is synergistic combination of Cisplatin derivatives with: (1) anticancer agents—Fluorouracil, Gemcitabine, Cytarabine, Fludarabine, Pemetrexed, Ifosfamide, Irinotecan, Topotecan, Etoposide, Amrubicin, Doxorubicin, Epirubicin, Vinorelbine, Docetaxel, Paclitaxel, Nab-Paclitaxel; (2) modulators of resistant mechanisms; (3) signaling protein inhibitors—Erlotinib; Bortezomib; Everolimus; (4) and immunotherapeutic drugs—Atezolizumab, Avelumab, Bevacizumab, Cemiplimab, Cetuximab, Durvalumab, Erlotinib, Imatinib, Necitumumab, Nimotuzumab, Nivolumab, Onartuzumab, Panitumumab, Pembrolizumab, Rilotumumab, Trastuzumab, Tremelimumab, and Sintilimab. An important approach for overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. The advantages of combination therapy are maximum removal of tumor cells in different phases; prevention of resistance; inhibition of the adaptation of tumor cells and their mutations; and reduction of toxicity. |
format | Online Article Text |
id | pubmed-9031877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90318772022-04-23 Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases Tsvetkova, Dobrina Ivanova, Stefka Molecules Review The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin, Heptaplatin, and Satraplatin. The literature data show that the strategies for the development of platinum anticancer agents and bypassing of resistance to Cisplatin derivatives and their toxicity are: combination therapy, Pt IV prodrugs, the targeted nanocarriers. The very important strategy for the improvement of the antitumor effect against different cancers is synergistic combination of Cisplatin derivatives with: (1) anticancer agents—Fluorouracil, Gemcitabine, Cytarabine, Fludarabine, Pemetrexed, Ifosfamide, Irinotecan, Topotecan, Etoposide, Amrubicin, Doxorubicin, Epirubicin, Vinorelbine, Docetaxel, Paclitaxel, Nab-Paclitaxel; (2) modulators of resistant mechanisms; (3) signaling protein inhibitors—Erlotinib; Bortezomib; Everolimus; (4) and immunotherapeutic drugs—Atezolizumab, Avelumab, Bevacizumab, Cemiplimab, Cetuximab, Durvalumab, Erlotinib, Imatinib, Necitumumab, Nimotuzumab, Nivolumab, Onartuzumab, Panitumumab, Pembrolizumab, Rilotumumab, Trastuzumab, Tremelimumab, and Sintilimab. An important approach for overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. The advantages of combination therapy are maximum removal of tumor cells in different phases; prevention of resistance; inhibition of the adaptation of tumor cells and their mutations; and reduction of toxicity. MDPI 2022-04-11 /pmc/articles/PMC9031877/ /pubmed/35458666 http://dx.doi.org/10.3390/molecules27082466 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tsvetkova, Dobrina Ivanova, Stefka Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title_full | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title_fullStr | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title_full_unstemmed | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title_short | Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases |
title_sort | application of approved cisplatin derivatives in combination therapy against different cancer diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031877/ https://www.ncbi.nlm.nih.gov/pubmed/35458666 http://dx.doi.org/10.3390/molecules27082466 |
work_keys_str_mv | AT tsvetkovadobrina applicationofapprovedcisplatinderivativesincombinationtherapyagainstdifferentcancerdiseases AT ivanovastefka applicationofapprovedcisplatinderivativesincombinationtherapyagainstdifferentcancerdiseases |